The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS

scientific article

The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3109/21678421.2013.817587
P698PubMed publication ID23952600

P2093author name stringAndrew A Wolff
Jeremy M Shefner
Lisa Meng
P2860cites workActivation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseasesQ28260224
Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosisQ58250570
P433issue7-8
P407language of work or nameEnglishQ1860
P921main subjectamyotrophic lateral sclerosisQ206901
serum concentrationQ126107668
P304page(s)582-5
P577publication date2013-12-01
P1433published inAmyotrophic Lateral Sclerosis and Frontotemporal DegenerationQ23928840
P1476titleThe relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS
P478volume14

Reverse relations

cites work (P2860)
Q46595019A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis
Q34554820ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?
Q38847200Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection.
Q33588537Amyotrophic lateral sclerosis disease modifying therapeutics: a cell biological perspective
Q38219475Assessment of disease progression and functional benefit in neurodegenerative disease: can we tell the difference?
Q47815494Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment
Q92813735Glial Cells-The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment
Q37701056Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases
Q38947721Strength Testing in Motor Neuron Diseases
Q28260629Targeting the sarcomere to correct muscle function

Search more.